Celecoxib/tramadol

Celecoxib/tramadol sold under the brand name Seglentis, is a fixed-dose combination of the anti-inflammatory celecoxib and the opioid tramadol used for the management and treatment of pain.[1]

Celecoxib/tramadol
Combination of
CelecoxibNonsteroidal anti-inflammatory drug (NSAID)
Tramadol hydrochlorideOpioid agonist
Clinical data
Trade namesSeglentis
Other namesE-58425
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • US: Schedule IV [1]

Developed by Spanish pharmaceutical company Esteve, it was approved for medical use in the United States in October 2021.[1][2][3]

References
  1. "Seglentis- celecoxib and tramadol hydrochloride tablet". DailyMed. Retrieved 8 January 2022.
  2. "Seglentis: FDA-Approved Drugs". U.S. Food and Drug Administration. Retrieved 18 October 2021.
  3. "Esteve Announces FDA Approval Of A Novel Co-Crystal Form Of Celecoxib And Tramadol For The Management Of Acute Pain". Esteve (Press release). 15 October 2021. Retrieved 18 October 2021.
  • "Celecoxib". Drug Information Portal. U.S. National Library of Medicine.
  • "Tramadol hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT03108482 for "Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial." at ClinicalTrials.gov


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.